Here’s What the Street Thinks About Alvotech (ALVO)

Alvotech (NASDAQ:ALVO) is one of the best stocks under $5 with huge upside potential. Alvotech (NASDAQ:ALVO) has received several rating updates from analysts since the release of its fiscal Q4 and full-year 2025 results. On March 23, Barclays cut the price target on the stock to $4 from $5 and maintained an Underweight rating on the shares. The firm told investors in a research note that it anticipates the shares to “remain in a holding pattern” pending U.S. approvals in fiscal Q4. It also stated that the company’s financial flexibility “bears watching”, given its high leverage.

The same day, UBS also cut the price target on Alvotech (NASDAQ:ALVO) to $6 from $10 while reiterating a Buy rating on the shares. It told investors in a research note that it is confident in the remediation plan outlined by the company’s management, and anticipates these approvals to occur by year-end 2026. The firm also stated that it believes the stock has largely reset after this sequence of negative developments, with expectations now meaningfully lower.

Alvotech (NASDAQ:ALVO) is a biotechnology company that develops and manufactures biosimilar medicines. The firm’s focus is on the development of its product candidates, with its operations divided into the following geographical segments: Europe, North America, Asia, and Other.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.